The Sinopharm and WuXi AppTec-backed, complement system-focused drug developer has hauled in $53.3m of new funding after emerging from stealth late last year.

The cardiovascular treatment device developer raised about $46m in a round led by Tencent and has now secured roughly $60m altogether.

Weill Cornell Medicine‘s monogenic diseases therapy developer Lexeo Therapeutics has made its public debut with $85m in series A financing.

Monogenic disease therapy developer Lexeo Therapeutics has publicly launched with financing from backers including Lundbeckfonden Ventures.

The CreditEase and Mouro Capital-backed payment technology provider lured personal finance firm OneMain Financial to co-lead its series C round.

LifeMine’s chairman and co-founder Rick Klausner has co-led a round that included multiple corporates and pushed the overall equity to $120m.

Sanofi and Mass General Brigham contributed to a round that pushed the immunotherapy developer's total funding to nearly $60m.

The McKesson-backed software provider secured $44m in series D funding alongside the acquisition of healthcare software developer Mavens.

BHP Ventures is co-leading the steel manufacturing technology developer's series B round, which has a $60m target for its close.

The O’Reilly Media-backed online campsite booking service achieved a $300m valuation in a series C round featuring Index Ventures and Bond Capital.